Key result
PFA adverse event reports primarily involve device malfunction, with ~32% resulting in patient injury.
Why the study?
To characterize individual-case medical device reports submitted to the FDA MAUDE database for commercially available pulsed-field ablation systems during early postmarket use.
Observational (n=10,976)
Early post-market surveillance of pulsed-field ablation systems in the FDA MAUDE database identifies device malfunctions and specific clinical adverse events, highlighting priorities for future prospective registries.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“And all of a sudden, you get at least some data indicating that the safety profile is maybe not as good as we thought, and that there is a new complication. The problem is that with atrioesophageal fistula, we understood it's related to energy delivered at the postererior wall, too much energy, and if it's too close to the esophagus, this is a risk for the fistula.”
“I think that it is important to look at real-world rates because now you're going to start using it in sicker and sicker patients. There are different technologies. There's learning curve issues, all of that. But you can't do it with the MAUDE database. That's my fundamental problem.”
MAUDE reports associate pulsed-field ablation with malfunctions and injuries; hypothesis-generating for prospective safety registries.
To characterize individual-case medical device reports submitted to the U.S. Food and Drug Administration Manufacturer and User Facility Device Experience database for commercially available pulsed-field ablation systems during early postmarket use. We analyzed reports received from February 1, 2024, through April 30, 2026. Master event, device, patient, patient problem code, device problem code, and narrative files were merged by report key. Literature-derived, clinical study-derived, false-positive, indeterminate, and exact duplicate narrative reports were excluded from the primary individual-case cohort. A prespecified hierarchy and targeted narrative review classified reporting phenotypes, reported clinical event categories, and device problem code categories. Duplicate-removal sensitivity analyses were performed. Of 11,563 potential reports, 10,976 individual-case reports formed the primary cohort. Device malfunction without identified patient injury accounted for 7,323 reports (66.7%), patient injury for 3,554 (32.4%), and unclear/no coded clinical event for 99 (0.9%). The most commonly reported clinical event categories were tamponade/perforation/pericardial effusion ( n = 1,014), arrhythmia/cardioversion/hemodynamic events ( n = 444), stroke/TIA/neurovascular events ( n = 383), coronary spasm/injury/ischemia ( n = 324), death ( n = 197), hemolysis/renal injury ( n = 114), phrenic/diaphragm injury ( n = 42), and plausible esophageal or upper gastrointestinal concerns ( n = 6). Duplicate removal did not materially change the report-category hierarchy. The value of this report-level surveillance analysis is characterization of report and event categories rather than incidence estimation. Future pulsed-field ablation registries should capture anticoagulation-related variables, patient-reported outcomes, lesion set and application burden, and adjudicated neurologic, coronary, renal, esophageal, and phrenic outcomes. PFA MAUDE reports identify electroporation-and workflow-relevant surveillance domains that should be prospectively captured, including anticoagulation variables, patient-reported outcomes, lesion set, application burden, and adjudicated clinical outcomes. FDA MAUDE reports after early pulsed-field ablation adoption identify clinically relevant post-market reporting phenotypes and define priorities for prospective PFA surveillance registries.
No takes yet. Share an insight, caveat, or question.
Gu et al. (2026) conducted an observational in Atrial fibrillation (n=10,976). Pulsed-field ablation was evaluated on Reporting phenotypes and clinical event categories. Among 10,976 FDA MAUDE reports for pulsed-field ablation, 66.7% involved device malfunction without patient injury and 32.4% involved patient injury.
Synapse has enriched 10 related papers. Consider them for comparative context: